Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
Primary Purpose
Influenza
Status
Completed
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
Vaccination with FLUVAL P
Sponsored by
About this trial
This is an interventional prevention trial for Influenza focused on measuring Influenza, Pandemic vaccine, Seasonal vaccine, Prevention, Influenza vaccine, Influenza in humans, Pandemic influenza in humans, Influenza vaccine for children
Eligibility Criteria
Inclusion Criteria:
- Children aged 6 to 36 months, both sexes;
- Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study;
- Capability of the legitimate representative of the volunteer to understand and comply with planned study procedures;
- Legitimate representative of the volunteer provide written informed consent prior to initiation of study procedures;
- Absence of existence of any exclusion criteria.
Exclusion Criteria:
- Known allergy to eggs or other components of the vaccine (in particular mercury);
- History of Guillain-Barré syndrome;
- Active neoplasm;
- Former or on-going immunosuppressive therapy;
- Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;
- Immunoglobulin (or similar blood product) therapy within 3 months prior to vaccination;
- Documented HIV, HBV or HCV infection;
- Chronic illness that, in the opinion of the investigator, may have effect on the participation in the study;
- Acute febrile respiratory illness within one week prior to vaccination;
- Vaccine therapy within 4 weeks prior to vaccination;
- Influenza vaccination within 6 months prior to vaccination;
- Experimental drug therapy within 1 month prior to vaccination;
- Past or current psychiatric disease of the legitimate representative that upon judgement of the investigator may have effect on the objective decision-making of the legitimate representative;
- Alcohol or drug abuse of the legitimate representative.
Sites / Locations
- "Csolnoky Ferenc" Veszprém County Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Vaccination with Fluval P
Arm Description
Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
Outcomes
Primary Outcome Measures
Incidence of adverse events
To assess tolerability/safety (incidence of adverse events) of the study drug after Day 28 following the vaccination.
Secondary Outcome Measures
Incidence of adverse events
To assess safety of the study drug after Day 180-210 following the vaccination.
Efficacy of the study drug
To assess the efficacy of the study drug by epidemiological follow-up of the participants until Day 180-210 following the vaccination.
Full Information
NCT ID
NCT01100294
First Posted
March 30, 2010
Last Updated
May 18, 2012
Sponsor
Fluart Innovative Vaccine Ltd, Hungary
1. Study Identification
Unique Protocol Identification Number
NCT01100294
Brief Title
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
Official Title
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
Study Type
Interventional
2. Study Status
Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
May 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fluart Innovative Vaccine Ltd, Hungary
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To determine the tolerability and safety of FLUVAL P monovalent influenza vaccine in children.
Detailed Description
This is an open, uncontrolled study to assess safety and tolerability of Fluval P monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL active ingredient in children of 6-36 months of age. The vaccination is not repeated.
Tolerability and safety (incidence of adverse events) of the study drug is assessed after Day 28 then after Day 180-210 following the vaccination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
Influenza, Pandemic vaccine, Seasonal vaccine, Prevention, Influenza vaccine, Influenza in humans, Pandemic influenza in humans, Influenza vaccine for children
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vaccination with Fluval P
Arm Type
Experimental
Arm Description
Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
Intervention Type
Biological
Intervention Name(s)
Vaccination with FLUVAL P
Other Intervention Name(s)
Influenza, Pandemic vaccine, Prevention, Influenza vaccine, Influenza in humans, Vaccination of children
Intervention Description
Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml (total 3 μg HA), single dose.
Primary Outcome Measure Information:
Title
Incidence of adverse events
Description
To assess tolerability/safety (incidence of adverse events) of the study drug after Day 28 following the vaccination.
Time Frame
28 days after vaccination
Secondary Outcome Measure Information:
Title
Incidence of adverse events
Description
To assess safety of the study drug after Day 180-210 following the vaccination.
Time Frame
180-210 days after vaccination
Title
Efficacy of the study drug
Description
To assess the efficacy of the study drug by epidemiological follow-up of the participants until Day 180-210 following the vaccination.
Time Frame
180-210 days after vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
36 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Children aged 6 to 36 months, both sexes;
Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study;
Capability of the legitimate representative of the volunteer to understand and comply with planned study procedures;
Legitimate representative of the volunteer provide written informed consent prior to initiation of study procedures;
Absence of existence of any exclusion criteria.
Exclusion Criteria:
Known allergy to eggs or other components of the vaccine (in particular mercury);
History of Guillain-Barré syndrome;
Active neoplasm;
Former or on-going immunosuppressive therapy;
Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;
Immunoglobulin (or similar blood product) therapy within 3 months prior to vaccination;
Documented HIV, HBV or HCV infection;
Chronic illness that, in the opinion of the investigator, may have effect on the participation in the study;
Acute febrile respiratory illness within one week prior to vaccination;
Vaccine therapy within 4 weeks prior to vaccination;
Influenza vaccination within 6 months prior to vaccination;
Experimental drug therapy within 1 month prior to vaccination;
Past or current psychiatric disease of the legitimate representative that upon judgement of the investigator may have effect on the objective decision-making of the legitimate representative;
Alcohol or drug abuse of the legitimate representative.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna Ősi, Dr.
Organizational Affiliation
Omninvest Ltd.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Éva Szabó, MD
Organizational Affiliation
"Csolnoky Ferenc" Veszprém County Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
"Csolnoky Ferenc" Veszprém County Hospital
City
Veszprém
ZIP/Postal Code
8200
Country
Hungary
12. IPD Sharing Statement
Learn more about this trial
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
We'll reach out to this number within 24 hrs